The pharmacokinetics of tacrolimus following its administration as monotherapy or in combination with corticosteroids or methotrexate to 31 BMT patients are presented. All patients received i. Tacrolimus is an immunosuppressive agent more recently studied in allogeneic liver transplantation and kidney transplantation, 2 either alone or in combination with corticosteroids, that has also been proven effective in the treatment of GVHD after BMT.
1
Tacrolimus is an immunosuppressive agent more recently studied in allogeneic liver transplantation and kidney transplantation, 2 either alone or in combination with corticosteroids, that has also been proven effective in the treatment of GVHD after BMT. [3] [4] [5] Tacrolimus may thus represent an alternative therapy for this indication.
The pharmacokinetics of tacrolimus in normal volunteers and in liver and kidney transplant patients have been pre-viously reported.
2,6-8 Recent reports have described in detail the safety and efficacy of tacrolimus used alone or in combination with methylprednisolone or methotrexate in the prevention of GVHD and included selected pharmacokinetic data. 9, 10 The present report presents a detailed evaluation of the p.o. and i.v. pharmacokinetics of tacrolimus in patients from these studies. In transplant patients, tacrolimus may be administered concomitantly with agents that can alter tacrolimus disposition. 2 In this context, tacrolimus has demonstrated a synergistic effect on human lymphocytes in vitro when combined with methylprednisolone, 11 suggesting a possible interaction upon concomitant administration of these agents. Since the immunosuppressive regimen in BMT patients involved the concomitant administration of methylprednisolone or methotrexate, the effects of these drugs on the pharmacokinetics of tacrolimus were evaluated.
Materials and methods

Patients
Participants in this study were patients with hematologic malignancies who received HLA-identical sibling donor bone marrow transplants and were on tacrolimus-based therapy. Each study patient was informed of the nature and risks of the study and gave written informed consent which was approved by an institutional review board. Pre-screening evaluation of potential study patients included vital signs, history and physical examination, height, weight, standard hematologic and biochemistry tests, and pregnancy tests for females. Eligible patients had negative pregnancy test and negative HIV tests. In addition, patients in the nonrandomized study (see below) had AST and ALT values р1.5 times upper limit of normal (ULN), total bilirubin within normal limits, and an estimated creatinine clearance у60 ml/min. Patients in the randomized study had AST, ALT and total bilirubin values р2 times ULN and a glomerular filtration rate у60 ml/min. Patients were excluded if they were recipient of T cell-depleted donor marrow.
Study design
This study obtained pharmacokinetic data from randomly selected subsets of patients in two phase II trials of tacrol-imus: 13 tacrolimus monotherapy patients from a nonrandomized open-label, uncontrolled study at four centers; and a randomized, single center, open-labeled, three-arm study of 18 patients. Patients in the randomized study were enrolled into one of three treatment groups; tacrolimus monotherapy (T), tacrolimus plus corticosteroids (T + P), or tacrolimus plus methotrexate (T + MTX). Randomization was stratified by age (Ͻ35 years and у35 years).
Patients in both studies received i.v. tacrolimus on an inpatient basis beginning 24 h prior to transplantation. A summary of the tacrolimus treatments is given in Table 1 . Patients in the nonrandomized study received a 4-h i.v. infusion of tacrolimus followed by a continuous infusion 24 h later. An i.v. pharmacokinetic profile of tacrolimus was determined from each patient following the 4-h infusion dose by collecting serial whole blood samples (3 ml) in tubes containing EDTA (or heparin) at 0 (immediately prior to the infusion) and 1, 2 and 4 h (during infusion) then at 4.25, 4.5, 4.75, 5, 6, 7, 8, 10, 12, 16 and 24 h from the beginning of the infusion. At the investigators judgement, patients were subsequently switched to p.o. dosing which was taken with water 1 h before, or 2-3 h after, meals. A p.o. tacrolimus pharmacokinetic profile was obtained during the first 8 weeks of treatment post-transplantation, following 4 days of stable dosing from whole blood samples taken immediately prior to the tacrolimus dose and then at 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h post-dose.
Patients in the randomized study received a continuous i.v. infusion of tacrolimus prior to transplantation which was continued post-transplantation (see Table 1 ). Patients were randomized to either continue on tacrolimus monotherapy, tacrolimus + methotrexate, or tacrolimus + corticosteroids. Patients receiving methotrexate were given an i.v. bolus dose of 15 mg/m 2 methotrexate on post-transplantation day 1 and 10 mg/m 2 on post-transplantation days 3, 6 and 11. Patients receiving corticosteroids were started on i.v. methylprednisolone (or p.o. prednisone) at a dose of 0.5 mg/kg per day beginning on post-transplantation day 7 and increased to 1 mg/kg per day from day 15 to day 28 then tapered to day 72. Steady-state i.v. tacrolimus pharmacokinetics were obtained from each patient on post-transplantation day 11 at 0 (prior to drug(s) administration) and then at 0.5, 1, 2, 4, 6, 8 and 12 h during the infusion. After conversion to p.o. therapy, whole blood samples were 
Sample analysis
Blood samples were drawn into tubes containing EDTA or heparin and immediately maintained at 4°C until assayed. Whole blood samples were extracted with methylene chloride and assayed for tacrolimus concentrations by an enzyme immunoassay (EIA) previously described. 12 The limit of quantitation (LOQ) for tacrolimus was 1 ng/ml (using 20 l whole blood samples per assay) with an interday relative standard deviation of 13-23%.
Pharmacokinetic analysis
Tacrolimus whole blood concentration vs time data were analyzed using model independent methods. 13 For each patient, the area under the blood concentration-time curve (AUC 0-t ) from time 0 to time t was calculated using the linear trapezoidal rule. The AUC 0-inf was calculated from AUC 0-t + AUC t-inf , where AUC t-inf was obtained from C final /␤, with C final being the last measured concentration and ␤ the terminal elimination rate constant. The value of ␤ was calculated from a least squares linear regression of the observed terminal concentration and time data pairs. The maximum concentration (C max ), time to maximum concentration (T max ), and concentration at steady-state (C ss ) were read from the observed data. Total body clearance (Cl) was calculated as dose/AUC 0-inf for the 4-h infusion data and as dose/C ss for the constant infusion data. The terminal elimination half-life (t 1/2 ) was calculated as ln(2)/␤; the volume of distribution (V) was calculated as Cl/␤. Bioavailability (F) was calculated for each patient as
Statistical analysis
Pharmacokinetic parameters and tacrolimus whole blood concentrations between treatment groups were compared using the Student's t-test or one way analysis of variance (ANOVA) with a level of significance of P Ͻ 0.05. Calcu-lations were performed using the statistical software program SYSTAT for Windows, Version 5 (Evanston, IL, USA). A correlation of steady-state trough blood concentration at 12 h (C min-12 h ) and AUC 0-12 was conducted. A correlation of C min at 0 h (C min-0 h ); ie 12 h after the previous dose to the subsequent AUC 0-12 , was also conducted.
Results
Patient characteristics
A summary of the patient demographic data for the 13 patients enrolled in the nonrandomized study of monotherapy tacrolimus pharmacokinetics, and the 18 patients were enrolled in the randomized, three treatment group study (T, T + P, and T + MTX) is shown in Table 2 .
Intravenous pharmacokinetics
The mean (s.d.) whole blood concentration profile for tacrolimus monotherapy following single 4-h i.v. infusion of 0.017 mg/kg (mean dose) is shown in Figure 1 . Tacrolimus whole blood concentrations were 28.7 Ϯ 35.6 ng/ml (mean Ϯ s.d.) at the end of the infusion then declined thereafter in an apparent polyexponential manner to 4.8 Ϯ 6.5 ng/ml at 24 h post-dose. The mean observed and calculated pharmacokinetic parameters are summarized in Table 2 . The mean AUC 0-24 of 216 ng/h/ml was 67% of the extrapolated AUC 0-inf . The mean terminal elimination half-life (t 1/2 ) was 18.2 h. The volume of distribution (V) of 1.67 l/kg indicated a moderate extent of distribution from the blood compartment; the total body clearance (Cl) was 71 ml/h/kg.
The mean steady-state tacrolimus whole blood concentrations for each treatment group (T, T + P, T + MTX) following a constant i.v. infusion of 0.013-0.015 mg/kg per 12 h are presented in Figure 2 . The mean C ss over the 12-h sampling period for the T group was 21.3 Ϯ 10.2 ng/ml compared to 29.4 Ϯ 23.8 ng/ml in the T + P group, and 25.4 Ϯ 18.0 ng/ml in the T + MTX group. There was no significant difference (P = 0.748) in the tacrolimus C ss among the three groups. The mean AUC 0-t of tacrolimus when administered alone (232 Ϯ 79 ng/h/ml) was lower than that for the T + P and T + MTX groups (323 Ϯ 196 and 326 Ϯ 221 ng/h/ml, respectively) but the difference among the groups was not significant (P = 0.637). Based on the continuous i.v. infusion C ss , the total body clearance (Cl) of tacrolimus in the monotherapy group was similar to that obtained with the single 4-h i.v. infusion (Table 3) . With the concomitant administration of methylprednisolone or methotrexate, tacrolimus Cl was decreased compared to that obtained with monotherapy, but this decrease was not statistically significant (P = 0.612).
Oral pharmacokinetics
The mean p.o. tacrolimus dose was similar in both studies ( Table 3 ). The ensuing mean (s.d.) blood concentration- (9) 49 (10) a Parameters for patients in the nonrandomized and randomized center studies, respectively. b C max for the 4-h infusion was the concentration at the end of the infusion, for the constant infusion was the mean concentration at steady-state and for p.o. doses was the highest observed concentration during a dosing interval. time profile of tacrolimus is shown in Figure 3 . The observed and calculated pharmacokinetic parameters from theses doses are summarized in Table 3 . The mean C max for tacrolimus monotherapy (44.6 and 41.8 ng/ml, nonran- domized group and T group, respectively) was similar to the C max attained with concomitant administration of methylprednisolone or methotrexate (44.0 and 37.3 ng/ml, respectively). The T max of tacrolimus was 2.3 Ϯ 1.5 h when given alone, whereas it was 2.6 Ϯ 1.9 h and 3.2 Ϯ 2.8 h with methylprednisolone and MTX, respectively. As seen in Table 3 the mean AUC 0-12 for the T, T + P and T + MTX groups were similar. The mean bioavailability for tacrolimus in the nonrandomized study was approximately 50% less than in the T group, similar to that in the T + P group and approximately 50% greater than in the T + MTX group. The data were highly variable and there were no statistically significant differences (P Ͼ 0.05) for any p.o. pharmacokinetic parameter among the groups.
Correlation of C min and AUC 0-12
The steady-state tacrolimus C min-0 h (pre-morning dose) and C min-12 h and AUC 0-12 values are given in Table 4 ; the correlation of C min (0 and 12 h) to the AUC 0-12 is shown in Figure 4 . The correlation (r) of C min-0 h to AUC 0-12 was 0.92 whereas it was 0.93 for C min-12 h to AUC 0-12 . 
Discussion
The data presented herein indicate that the p.o. pharmacokinetic profile of tacrolimus in BMT patients was similar at steady-state (ie between weeks 3 and 8 post-transplantation with stable dosing for 4 consecutive days) or administered as a single dose, ie following administration as a single 4-h i.v. infusion, or as a continuous i.v. infusion. At 24 h after the 4-h i.v. infusion, tacrolimus blood concentrations declined to approximately 17% of the concentration at the end of the infusion, even though the terminal t 1/2 in this group of patients was approximately 18 h. This is consistent with a polyexponential elimination profile having one or more rapid distribution phases and a longer elimination phase, as previously reported.
14 The total body clearance with the 4-h i.v. infusion and the constant i.v. infusion was in good agreement (71 and 75 ml/h/kg, respectively). Chronic drug administration can result in drug accumulation as a function of a patient's physiological status. In this context, the results of the present study suggest little or no potential for tacrolimus accumulation as indicated by the C ss . The estimated C ss (adjusted for dose) calculated from the 4-h i.v. infusion data (19.5 ng/ml) was similar to that observed with the continuous i.v. infusion (21.3 ng/ml). The co-administration of methylprednisolone did not alter the overall i.v. tacrolimus whole blood concentration-time profile (Figure 2 ) nor the calculated pharmacokinetic parameters. Similar results have been reported in rabbits. 15 Coadministration of methotrexate also showed a lack of effect.
The p.o. administration of tacrolimus alone or with methylprednisolone or methotrexate resulted in similar values for C max , T max , and AUC 0-t in all cohorts. The bioavailability of tacrolimus appeared to decrease with concomitant administration of methylprednisolone or methotrexate, with methotrexate showing the greater effect. It is possible that methotrexate has an effect on gastro-intestinal motility 16 and thus may explain, in part, the apparent decreased absorption of tacrolimus. However, because of the small number of patients and data variability, no definitive conclusions can be obtained. The bioavailability in the monotherapy group was higher (31 and 49%) than that reported for healthy volunteers (18%) 2 or liver transplant patients (25%) 6 but also showed a wide range. In the non-randomized study, one patient had tacrolimus blood concentrations that were considerably higher relative to those of the other patients in the group for both i.v. and p.o. administrations. For the i.v. administration the AUC for this patient was 788 g/h/ml compared to a mean (s.d.) 164 Ϯ 61 g/h/ml for the rest of the group; for the p.o. administration, the respective comparison was 1473 g/h/ml vs 299 Ϯ 174 g/h/ml. It should be pointed out that data for this patient was included in all pharmacokinetic calculations and tabulations and contributed to the variability of the C max and AUC parameters (see Table 3 ). It should also be stated that, even though the C max , AUC (and C min ) was high, the adverse event profile of this patient was similar to that of other patients in the group.
In bone marrow transplant patients, t 1/2 and V was similar to that in kidney transplant patients (17.6 h and 1.58 l/kg) 8 but greater than in liver transplant patients (12.1 h and 0.9 l/kg). 7 Total Cl in bone marrow transplant patients was greater than in liver transplant patients (54.1 ml/h/kg) but less than in kidney transplant patients (95.2 ml/h/kg). 8 Taken collectively, the indication is that the pharmacokinetics of tacrolimus are to some extent dependent on the transplant patient population. 2 The establishment of a correlation of trough blood concentration and AUC as an index of patient exposure to drug has an important implication for therapeutic drug monitoring. 17 In many cases, it is difficult or impossible to obtain serial blood samples for the determination of an AUC, whereas a single, trough sample can be obtained with relative ease. In solid organ transplants, the principle of therapeutic drug monitoring is well established as a guide to evaluate a patient's exposure to tacrolimus and as a guide for dose adjustment. 18, 19 In this context, the use of trough blood concentrations (C min ) for therapeutic drug monitoring of tacrolimus and a good correlation of C min and AUC has been reported. 20, 21 The data presented indicate that, in bone marrow transplantation patients on tacrolimus therapy, trough concentrations are a good index of patient exposure to tacrolimus. The coefficient of correlation (r) of steady-state C min-12 h to AUC 0-12 was 0.93. A good correlation was also found using C min-0 h (r = 0.92), therefore trough level monitoring may be performed with either the morning or evening tacrolimus dose, provided the dose is stable (Figure 4) . The pharmacokinetic profile of tacrolimus has been characterized in BMT patients receiving monotherapy and combination therapy with either methotrexate or steroids. This profile can be used to design dosing regimens in this population with subsequent individualized dose adjustments based on trough level monitoring.
